Targeting the GPR183/EBI2‒oxysterol axis in tuberculosis: Immunometabolic regulation and prospects for host‐directed therapy
Abstract Background Tuberculosis (TB), caused predominantly by Mycobacterium tuberculosis (Mtb), remains a major global health challenge despite the availability of antimicrobial chemotherapy. Drug‐resistant TB, latent infection, immunopathology and metabolic comorbidities such as diabetes continue to undermine treatme...